Loading...
Loading...
MDWD| Name | Value |
|---|---|
| Revenues | 11.6M |
| Cost of Revenue | 3.5M |
| Gross Profit | 8.2M |
| Operating Expense | 6.3M |
| Operating I/L | 1.8M |
| Other Income/Expense | -9.2M |
| Interest Income | -0.0M |
| Pretax | -7.4M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -7.5M |
MediWound Ltd. is a biopharmaceutical company specializing in the development, manufacturing, and commercialization of innovative bio-therapeutic solutions for tissue repair and regeneration. The company's flagship product, NexoBrid, is marketed for the removal of eschar in adults with deep partial- and full-thickness thermal burns. Additionally, MediWound is advancing EscharEx, which has completed Phase II clinical trials for debridement of chronic and hard-to-heal wounds, and MW005, currently in phase I/II for the treatment of low-risk basal cell carcinoma.
